Company: PIII
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001140361-25-016302
Chunk: 48

Company: P3 Health Partners Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 48
---
 Average Non- 
 CEO NEOs     |
| Increase/deduction for Awards Granted during Prior FY that Vested During Applicable FY, determined based on change in ASC 718 Fair Value from Prior FY End to Vesting Date |     |    — |     | —            |     |    — |     |      -34,500 |     |            — |     | —            |
| TOTAL ADJUSTMENTS                                                                                                                                                          |     |   $— |     | $(360,935)   |     |   $— |     |   $(345,750) |     | $(6,397,533) |     | $(90,194)    |

| (3) | The amounts reflect the cumulative total shareholder return (“TSR”) of our Common Stock at the end of each fiscal year. The TSR value listed in each year reflects what the cumulative value of $100 would be if invested on December 31, 2021. TSR is calculated on a cumulative basis by dividing the sum of the cumulative amount of dividends for the measurement period, assuming dividend reinvestment (if any), and the difference between the Company’s share price at the end and the beginning of the measurement period by the Company’s share price at the beginning of the measurement period. Historical stock price performance is not necessarily indicative of future stock performance. |

| (4) | The dollar amounts reported represent the net income (loss) reflected in the Company’s audited financial statements for the applicable year. |

Relationship Between Compensation Actually Paid and Financial Performance Measures

32

TABLE OF CONTENTS

Practices for the Timing of Awards as They Relate to the Disclosure of Material Non-Public Information We do not grant equity awards in anticipation of the release of material nonpublic informationand we do not time the release of material nonpublic information based on equity award grant dates or for the purpose of affecting the value of executive compensation.In addition, we do not take material nonpublic information into account when determining the timing and terms of such awards. Although we do not have a formal policy with respect to the timing of our equity award grants, the Compensation and Nominating Committee anticipates that it will grant most awards on a predetermined annual schedule. In fiscal 2024, we granted an award of stock options to one of our named executive officers in the period beginning four business days before the filing or furnishing of a periodic report or current report disclosing material nonpublic information and ending one business day after the filing or furnishing of any such report with the SEC when we